No Data
Jimin Health (603222.SH): A subsidiary plans to accept relocation compensation.
On December 31, Gelonghui announced that Jimin Health (603222.SH) has completed the non-public issuance of Stocks fundraising for the "Annual Production of 850 Million Safe Syringes and Safe Injection Needle Technology Transformation Project". The office location of its wholly-owned subsidiary, Jumin Biotechnology Co., Ltd. (referred to as "Jumin Biotechnology"), has been relocated from "1888 Huhang Highway, Fengxian District, Shanghai" to "398 Renjie South Road, Fengxian, Shanghai". The "House Rental Agreement" between Jumin Biotechnology and its affiliate, Shanghai Shuangge Industrial Co., Ltd. (referred to as "Shanghai Shuangge Industrial"), has also been terminated. Given that:
Jimin Health (603222.SH): Re-recognized as a high-tech enterprise.
Glonghui, December 26丨Jimin Health (603222.SH) announced that according to the notice issued by the Office of the Leadership Group for the Management of National High-tech Enterprise Recognition on December 26, 2024, regarding the filing of high-tech enterprises recognized by Zhejiang Province in 2024, the company has once again passed the re-recognition of high-tech enterprises, with a certificate number of GR202433007778, issuance date of December 6, 2024, valid for three years. This recognition as a high-tech enterprise is a re-recognition following the expiry of the original certificate.
Chimin Health Management Signs 10-Year Manufacturing Deal
Chimin Health Management Co., Ltd.'s (SHSE:603222) Last Week's 12% Decline Must Have Disappointed Retail Investors Who Have a Significant Stake
Jimin Health (603222.SH): plans to be involved in the OEM production of safety injection needles and safety syringes and other products.
On December 19, Gelonghui announced that Jimin Health (603222.SH) has signed a "Manufacturing Agreement" with USA Retractable Technologies, Inc. (abbreviated as "RTI") for the subcontracted production of products such as safe injection needles and safe syringes. The company's wholly-owned subsidiary, Jumin Biotechnology Co., Ltd. (including its predecessor), has been the OEM manufacturer for safe injection needles and safe syringes for USA RTI since 2004, marking a cooperation of 20 years to date. This time
Is Chimin Health Management (SHSE:603222) Using Too Much Debt?
Chimin Health Management Co., Ltd.'s (SHSE:603222) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
No Data
